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Background: We examined preoperative kinesin II-associated protein (KAP1), TIMP metallopeptidase inhibitor 1
(TIMP1) and stanniocalcin 2 (STC2) expression levels in patients with gastric cancers to assess their clinical
application for diagnosing and monitoring diseases.
Methods: Real-time reverse transcription-polymerase chain reaction was used to detect the expression levels of
KAP1, TIMP1, STC2, talin 2 (TLN2), sushi-repeat-containing protein, X-linked 2 (SRPX2) and secreted protein, acidic,
cysteine-rich (SPARC) in the patients’ peripheral blood karyocytes. The data were analyzed with receiver operating
characteristics (ROC) curves.
Results: A total of 112 patients with gastric cancer, 42 patients with recurrence and 107 healthy volunteers were
recruited. There were significant correlations between KAP1, TIMP1 and STC2 levels, and TNM tumor stages and
distant metastases. The area under the ROC curves (AUC) of KAP1 was 0.803 ± 0.040 (P = 0.0001), the AUC of TIMP1
was 0.767 ± 0.043 (P = 0.0001) and the AUC of STC2 was 0.769 ± 0.045 (P = 0.0001), thus differentiating preoperative
gastric cancer patients from healthy volunteers by ROC curve analysis. The AUC of STC2 was 0.739 ± 0.070 (P =
0.004) and the AUC of KAP1 was 0.418 ± 0.088 (P = 0.319), thus differentiating recurrence of gastric cancer from
healthy volunteers by ROC curve analysis. High TIMP1 and STC2 expression levels were suspected to be poor
prognostic factors of disease recurrence in patients with gastric cancer.
Conclusions: KAP1, TIMP1 and STC2 expression levels may be potential biomarkers for the screening, diagnosis,
prognosis and surveillance of gastric cancer.
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The overall 5-year survival rate in China for patients
with gastric cancer is low, at 40%, and the rate of lymph
node metastasis is higher (50 to 75%) [1]. Patients who
had undergone potentially curative surgery retain the
risk of recurrence mainly because of tumor dissemina-
tion via the blood or lymphatic circulations. To improve
the cure rates for patients with gastric cancer, the pri-
mary tumors must be detected at an early stage, and
recurrent disease must be diagnosed while it is still mi-
nimal or clinically occult; micrometastases are currently* Correspondence: zhaozhongsheng1950@163.com
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reproduction in any medium, provided the orundetectable by conventional methods [2,3]. Conven-
tional serum markers, however, lack sufficient sensitivity
and specificity to facilitate early detection of cancer. To
improve the poor survival outcome and to permit earlier
diagnosis, there is a need for new and more sensitive
biomarkers than those currently available, such as carci-
noembryonic antigen and CA19-9 [4].
TIMP metallopeptidase inhibitor 1 (TIMP1) belongs to
the tissue inhibitor of metalloproteases (TIMP) gene
family. The proteins encoded by this gene family are nat-
ural inhibitors of the matrix metalloproteinases (MMPs),
a group of peptidases involved in degradation of the
extracellular matrix. In addition to its inhibitory role
against most of the known MMPs, the encoded protein
is also able to promote cell proliferation in a wide rangetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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TIMP1 has been shown to be overexpressed in both liver
and peritoneal metastases from patients with colorectal
adenocarcinoma [5] and malignant thyroid neoplasms [6].
Stanniocalcin 2 (STC2) encodes a secreted, homodime-
ric glycoprotein that is expressed in a wide variety of tis-
sues and may have autocrine or paracrine functions. The
protein may play a role in the regulation of renal and in-
testinal calcium and phosphate transport, cell metabolism,
or cellular calcium/phosphate homeostasis. Constitutive
overexpression of human STC2 in mice resulted in pre-
and postnatal growth restriction, reduced bone and ske-
letal muscle growth, and organomegaly. Expression of this
gene is induced by estrogen and altered in some breast
cancers [7]. The expression of STC2 was significantly cor-
related with lymph node metastasis, lymphatic invasion,
and distant metastasis of esophageal squamous cell cancer
[8] and colorectal cancer [9].
The protein encoded by KAP1 mediates transcriptional
control by interacting with the Kruppel-associated box
repression domain found in many transcription factors.
The protein, a member of the tripartite motif family, lo-
calizes to the nucleus and is thought to associate with
specific chromatin regions. This tripartite motif includes
three zinc-binding domains, a RING, a B-box type 1 and
a B-box type 2, and a coiled-coil region. KAP1 plays an
important role in progression to peritoneal carcinoma-
tosis in gastric cancer patients [10].
In our previously study, KAP1, TIMP1, STC2, talin 2
(TLN2), sushi-repeat-containing protein, X-linked 2
(SRPX2), ITGB1 and secreted protein, acidic, cysteine-rich
(SPARC) were selected by the Affymetrix GeneChip™ HG-
U133A2.0 array, and were upregulated (ratio ≥2) in gastric
tumor tissue [11] (Affymetrix, Santa Clara, California,
United States). In this study, we detected the expression
of KAP1, TIMP1, STC2, TLN2, SRPX2, integrin beta 1
(ITGB1) and SPARC mRNAs in peripheral blood samples
from pre-operative gastric cancer patients, patients with
recurrence, and healthy volunteers. We compared the re-
lationships between these results and clinical findings to
assess the diagnostic value of the biomarkers in these
patients.
Methods
Patients and peripheral blood samples
A total of 112 patients with gastric cancer and 42 pa-
tients with recurrence, diagnosed and treated between
January 2006 and December 2010 at Zhejiang Provincial
People’s Hospital, were enrolled in this study. The me-
dian age of the gastric cancer patients was 60 years
(range, 36 to 87 years), and the study comprised 77
males and 35 females. The median age of patients with
recurrence was 64 years (range, 51 to 65 years), and this
subset comprised 31 males and 11 females. One hundredand seven healthy volunteers who visited the hospital for
a health examination and who had normal appearance
of the gastric mucosa on gastroscopic examination were
also enrolled. The healthy controls comprised 76 males
and 31 females, with a median age of 59 years (range, 35
to 86 years).
All patients had follow-up records from the date of
their operation, with a follow-up deadline of November
2011. None of the 112 patients with gastric cancer had
received preoperative chemotherapy or radiotherapy, but
were receiving radical or palliative gastrectomy. Seventy
of these patients (62.5%) were resected with tumor-free
resection margins (R0), while the remaining 42 patients
(37.5%) were resected with R1 or R2. Following surgery,
patients with stage I to III tumors received adjuvant
chemotherapy, while patients with stage IV tumors re-
ceived systemic chemotherapy with various combina-
tions of regimens. Ten patients with recurrence received
a radical operation again, and all received systemic
chemotherapy. Of the 112 gastric patients with cancer,
12.5% (14 of 112) were classified as stage I, 35.71% (40
of 112) were stage II, 34.82% (39 of 112) were stage III,
and 16.96% (19 of 112) were stage IV (Table 1). The
clinicopathological findings were determined according
to classification of malignant tumors as set out by the
World Health Organization for gastric cancer. The study
was approved and monitored by the ethics committee of
our hospitals, and informed consent was obtained from
each patient and healthy volunteer.
Total RNA preparation
A 2-ml sample of peripheral blood from all of subjects
was collected in test tubes containing sodium citrate.
Wang et al. World Journal of Surgical Oncology 2013, 11:81 Page 3 of 8
http://www.wjso.com/content/11/1/81Total RNA from peripheral blood karyocyte was isolated
using QIAamp RNA Blood Mini Kits (Cat. No: 52304,
QIAGEN, Hilden, Germany) following the manufac-
turer’s protocol.
Real-time quantitative PCR
The expressions of KAP1, TIMP1, STC2, TLN2, SRPX2
and SPARC in peripheral blood from 82 patients with
gastric cancer, 24 patients with recurrence and 69
healthy volunteers were confirmed by RT-PCR(reverse
transcription PCR). Total RNA was extracted and
cDNAs were reverse-transcribed by RevertAid™ reverse
transcriptase. Real-time PCR was carried out using the
ABI PRISM 7700 Sequence Detection System (Life
Technologies, Grand Island, New York, United States) at
50°C for 2 min, 95°C for 10 min, followed by 50 cycles at
95°C for 15 s, and 60°C for 1 min. The primers are listed
in Table 2. The expression of GAPDH was used to nor-
malize that of the target genes. Each assay was done in
triplicate, the average was calculated, and the expression
level of targets mRNA was expressed as 2–ΔCt, ΔCt =Ct
(targets mRNA) −Ct(GAPDH).
Statistical analysis
Statistical analysis was performed using SPSS 16.0 (SPSS
Inc, Chicago, United States). The level of significance
was set at P < 0.05. ROC (receiver operation characteris-
tics) curves were constructed by calculating the sensiti-
vities and specificities of a biomarker or the diagnostic
score of a logistical regression model at different cut-off
points for differentiating gastric cancer cases from
healthy volunteers. The area under the ROC curves
(AUC) was statistically interpreted as the probability to
correctly distinguish patients with gastric cancer from
normal subjects. An area of 1.0 represented a perfect
test, and an area of 0.5 represented a worthless test. The
P value was the probability that the sample AUC was
found when, in fact, the true (population) AUC was 0.5
(null hypothesis: area = 0.5). If P was low (P < 0.05), then
it was concluded that the AUC was significantly different
between the two groups. The ROC curves were used to








GAPDH TGAAGGTCGGAGTCAACGGtest for overall accuracy) [12]. The cutoff value cor-
responded to the optimal diagnostic accuracy (the
highest sum of the respective values for sensitivity and
specificity) [6].Results
The diagnostic efficacy of KAP1, TIMP1, STC2, TLN2, SRPX2
and SPARC in patients with gastric cancer
To evaluate the diagnostic value of KAP1, TIMP1, STC2,
TLN2, SRPX2, ITGB1 and SPARC expression levels in the
diagnosis of patients with gastric cancer, the AUC value
from ROC curve analysis was determined (Figure 1). The
clinical values were assessed by differentiating preoperative
gastric cancer patients from healthy volunteers. The AUC
of KAP1 was 0.803 ± 0.040 (P = 0.0001; 95% CI 0.724 to
0.881), the criterion value (cutoff value) was 0.0386 with a
sensitivity of 76.9%, and the specificity was 76.6%. The
AUC of TIMP1 was 0.767 ± 0.043 (P = 0.0001; 95% CI
0.682 to 0.851), the criterion value (cutoff value) was 0.215
with a sensitivity of 61.5%, and the specificity was 83.0%.
The AUC of STC2 was 0.769 ± 0.045 (P = 0.0001; 95% CI
0.680 to 0.858), the criterion value (cutoff value) was 0.01
with a sensitivity of 94.9%, and the specificity was 53.2%.
The AUC of SRPX2 was 0.507 ± 0.059 (P = 0.901; 95% CI
0.392 to 0.621). The AUC of SPARC was 0.452 ± 0.055
(P = 0.372; 95% CI 0.345 to 0.559). The AUC of TLN2 was
0.485 ± 0.056 (P = 0.783; 95% CI 0.376 to 0.594).Expression of KAP1, TIMP1 and STC2 in patients with
gastric cancer and healthy volunteers
According to the criterion value (cutoff value), the higher
expression of KAP1 was detected in 21 of 107 (19.6%)
healthy volunteers and in 99 of 112 (88.4%) patients with
gastric cancer (χ2 = 104.5, P = 0.0001) (Figure 2). The
higher expression of TIMP1 was detected in 19 of 107
(17.8%) healthy volunteers and in 100 of 112 (89.3%) pa-
tients with gastric cancer (χ2 = 112.8, P = 0.0001). The
higher expression of STC2 was detected in 20 of 107
(18.7%) healthy volunteers, and in 101 of 112 (90.2%) pa-








Figure 1 Receiver operation characteristics (ROC) curve of KAP1, TIMP1 and STC2 in peripheral blood of patients with gastric cancer
and healthy volunteers. The clinical values were assessed by differentiating 112 preoperative gastric cancer patients from 107
healthy volunteers.
Wang et al. World Journal of Surgical Oncology 2013, 11:81 Page 4 of 8
http://www.wjso.com/content/11/1/81Relationship between expression of KAP1, TIMP1 and STC2
in patients with gastric cancer and clinical characteristics
We examined the correlation between the expression
levels of KAP1, TIMP1 and STC2 and clinical parameters.
No significant associations were found between these
three mRNAs, and gender, tumor location, tumor size,
Lauren classification, histology classification, differenti-
ation or distant metastasis (P >0.05). There were, however,
significant association between the three mRNAs and
TNM stages and lymph node metastasis (Table 3).
The diagnostic efficacy of KAP1, TIMP1, STC2, TLN2, SRPX2
and SPARC in patients with recurrence of gastric cancer
To evaluate the diagnostic value of KAP1, TIMP1, STC2,
TLN2, SRPX2 and SPARC expression levels in theFigure 2 The gel electrophoresis of KAP1, TIMP1, STC2, TLN2, SRPX2, adiagnosis of patients with recurrence of gastric cancer,
the AUC value from ROC curve analysis was deter-
mined (Figure 3). The AUC of TIMP1 was 0.761 ±
0.073 (P = 0.002; 95% CI 0.619 to 0.903), the criterion
value (cutoff value) was 0.214 with a sensitivity of
64.7%, and the specificity was 83.0%. The AUC of
STC2 was 0.739 ± 0.070 (P = 0.004; 95% CI 0.603 to
0.875), the criterion value (cutoff value) was 0.0129
with a sensitivity of 94.1%, and the specificity was
55.3%. The AUC of KAP1 was 0.418 ± 0.088 (P = 0.319;
95% CI 0.246 to 0.59). The AUC of TLN2 was 0.441 ±
0.083 (P = 0.475; 95% CI 0.279 to 0.603). The AUC of
SRPX2 was 0.453 ± 0.074 (P = 0.569; 95% CI 0.308 to
0.599). The AUC of SPARC was 0.416 ± 0.080 (P =
0.308; 95% CI 0.26 to 0.573).nd SPARC in patients with gastric cancer and healthy volunteers.
Table 3 Relationship of KAP1, TIMP1 and STC2 expression with pathological parameters of tumor
Clinical parameters KAP1 TIMP1 STC2
Low High χ2 P Low High χ2 P Low High χ2 P
N 13 99 12 100 11 101
Gender 1.52 0.22 0.68 0.41 3.08 0.079
Male 7 70 7 70 5 72
Female 6 29 5 30 6 29
Location 0.184 0.91 1.82 0.40 1.99 0.369
Proximal 1 11 0 12 0 12
Middle 4 32 5 31 5 31
Distal 8 56 7 57 6 58
Size 0.227 0.633 0.156 0.693 0.484 0.487
<5 cm 5 45 6 44 6 44
≥5 cm 8 54 6 56 5 57
Lauren classification 0.56 0.45 0.55 0.46 0.037 0.85
Intestinal 8 50 5 53 6 52
Diffuse 5 49 7 47 5 49
Histology 1.53 0.675 5.376 0.146 2.62 0.454
Papillary adenocarcinoma 0 5 0 5 0 5
Tubular adenocarcinoma 11 69 12 68 10 70
Mucinous adenocarcinoma 1 15 0 16 1 15
Signet-ring cell carcinoma 1 10 0 11 0 11
Histologic differentiation 0.013 0.91 1.97 0.16 0.10 0.75
Well-moderately 4 32 6 30 4 32
Poorly-undifferentiated 9 67 6 70 7 69
TNM Stages 24.31 0.001 36.46 0.001 20.26 0.001
I 7 7 8 6 6 8
II 4 36 2 38 3 37
III 2 37 2 37 1 38
IV 0 19 0 19 1 18
Lymph node metastasis 48.37 0.001 24.15 0.001 41.32 0.001
No 7 1 5 3 6 2
Yes 6 98 7 97 5 99
Distant metastasis 0.898 0.343 2.746 0.098 0.537 0.464
No 12 81 12 81 10 83
Yes 1 18 0 19 1 18
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The outcome of patients with gastric cancer depends on
tumor stage at the time of diagnosis [13]. Endoscopic
examination is the most reliable method for the diagno-
sis of gastric cancer; however, the feasibility and cost ef-
fectiveness of this invasive approach in most countries
remain questionable [14]. A simple diagnostic test, such
as a serum biomarker assay, could facilitate screening
for gastric cancer. Currently, however, there are no
serum biomarkers that are sufficiently sensitive and spe-
cific for the routine diagnosis of gastric cancer. Thesensitivities of tumor markers such as CEA, CA 19–9 and
CA 72–4 are low (20 to 30%) [15-17]. O’Sullivan et al.
[18] suggested that preoperative detection of microme-
tastases may reflect either transient shedding of cells,
metastatic potential or residual disease.
In this study, we detected the expression levels of
KAP1, TIMP1, STC2, TLN2, SRPX2 and SPARC mRNAs
in peripheral blood samples from pre-operative gastric
cancer patients, those with recurrence, and in healthy
volunteers. ROC curve analysis was used to evaluate the
diagnostic value of the expression levels of these genes
Figure 3 Receiver operation characteristics (ROC) curve of the TIMP1 and STC2 in peripheral blood of patients with recurrence of
gastric cancer and healthy volunteers. The clinical values were assessed by 42 patients with recurrence of gastric cancer from 107
healthy volunteers.
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patients with recurrence from healthy volunteers. The
study showed that KAP1, TIMP1 and STC2 expression
levels could differentiate preoperative gastric cancer pa-
tients from healthy volunteers, and that TIMP1 and
STC2 could differentiate preoperative gastric cancer pa-
tients with recurrence from healthy volunteers.
Previous studies showed that TIMP1 was overex-
pressed in both liver and peritoneal metastases from pa-
tients with colorectal adenocarcinoma, melanoma and
malignant thyroid neoplasms. TIMP1 showed significant
increase in immunoreactivity in the colorectal carcin-
omatous epithelium compared with the adenomatous
epithelium [19]. TIMP1 was overexpressed in both liver
and peritoneal metastases from patients with colorectal
adenocarcinoma [20]). The level of TIMP1 mRNA ex-
pression was found to be an independent diagnostic
marker of malignant thyroid neoplasms [21]. In our
study, the expression levels of STC2 in patients with gas-
tric cancer were significantly higher than those in
healthy volunteers. There were significant correlations
between the expression levels of STC2, and TNM stages
and lymph node metastasis. The level of serum TIMP-1
in patients with melanoma has previously been shown tobe significantly higher than in controls, leading to the
speculation that serum level of TIMP-1 may be a new
useful marker for melanoma progression [22].
Solid tumor progression is usually associated with hy-
poxia. STC2 has been suggested as a novel target of oxi-
dative stress response to protect cells from apoptosis.
The expression of STC2 has been reported to be highly
correlated with human cancer development. The identi-
fication and functional analysis of STC2 upregulation by
hypoxia, a feature of the tumor microenvironment,
sheds light on a possible role for STC2 in tumors. The
cell proliferation was reduced in STC2-silenced cells but
was increased in STC2-overexpressing hypoxic cells [23].
The stable expression of exogenous STC2 promoted
epithelial-mesenchymal transition in hypoxic conditions.
When STC2 was stably transfected into cells, they
showed a high degree of motility with fibroblast morph-
ology under hypoxic condition, and a high degree of in-
vasiveness in hypoxia. The finding provides evidence
that STC2 is a positive regulator of tumor progression in
hypoxic conditions [24]. In our study, the expression of
STC2 in patients with gastric cancer was significantly
higher than in healthy volunteers. There were significant
correlations between the expression of STC2, and TNM
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shown that the expression of STC2 in colorectal cancer tis-
sue was higher than in corresponding normal colorectal
epithelial tissue. The high expression of STC2 was corre-
lated with lymph node metastasis, lymphatic invasion,
tumor depth, tumor size, AJCC stage classification and
worse overall survival rates [9]. STC2 was upregulated at
the mRNA and protein levels in renal cell carcinoma [25].
STC2 was expressed in invasive breast tumor cells, while
univariate survival analysis revealed that expressions of
STC2 were correlated with longer disease-free survival [26].
In our study, we focused on the KAP1 expression pat-
terns in peripheral blood from patients with gastric can-
cer. The levels of KAP1 in the gastric cancer group were
found to be significantly higher than those in the healthy
volunteer group. There were significant correlations bet-
ween the expression of KAP1, and TNM stages and dis-
tant metastasis. The study by Yokoe et al. showed that
the expression of KAP1 was significantly higher in can-
cerous tissues than in non-cancerous tissues. Patients
with high KAP1 expression showed a higher incidence
of peritoneal carcinomatosis and significantly poorer
overall survival compared with patients with low KAP1
expression. Multivariate analysis revealed that high
KAP1 expression was an independent prognostic factor.
Intriguingly, high KAP1 expression was also an inde-
pendent factor for peritoneal carcinomatosis [10]. To
evaluate the diagnostic value of KAP1 in the diagnosis of
patients with recurrence of gastric cancer, the AUC
value from ROC curve analysis was determined. The
AUC of KAP1 was 0.418 ± 0.088 (P = 0.319), indicating
that expression levels of KAP1 could not distinguish re-
currence of gastric cancer from cancer, probably because
the number of recurrences of gastric cancer were too
few. The proliferation rate was impaired and resistance
to anoikis was decreased after knockdown of KAP1 in
the gastric cancer cell lines AZ521 and KATO III [10].
KAP1 contributes to the negative regulation of E2F1 and
may serve as a partial backup to prevent E2F1-mediated
apoptosis in the absence of pRb [27].
Previous studies have shown that SRPX2 and SPARC
were overexpressed in gastric cancer tissues [28-30],
while TLN2 was upregulated in breast carcinomas tis-
sues [31]; however, no studies investigating the expres-
sion of TLN2, SRPX2, and SPARC in peripheral blood
have been reported. Our study showed that TLN2,
SRPX2 and SPARC expression were detected in gastric
cancer, but expression of TLN2, SRPX2 and SPARC
could not differentiate preoperative gastric cancer pa-
tients from healthy volunteers.
KAP1, TIMP1 and STC2 appear to have a role in the
progression to metastatic disease in gastric cancer. Pre-
operative KAP1, TIMP1 and STC2 expression levels in
peripheral blood were related to cancer stage and maybe markers of tumor invasion, lymph node metastasis
and TNM stage. In particular, high TIMP1 and STC2
expression levels could be poor prognostic factors of di-
sease recurrence in patients with gastric cancer.
Conclusions
Expression levels of KAP1, TIMP1 and STC2 are poten-
tially useful as clinical biomarkers for the screening,
diagnosis, prognostic and surveillance of gastric cancer.
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